Member Info for MaryBr190

Departing with immediate effect. Significant drop, maybe same again tomorrow but picked up a small quantity sub £3.

1st trance of 10 on each 10% fall.

Just for fun but intend to scale in.

Each bounce and fall, particularly with the 20% movements either way is a traders dream.

Big fall I buy, large rise I reduce.

Ramp or deramp I do not care but will reduce average towards Zero eventually.

I just keep adding.

Like Wood Group today , all it takes is a change in sentiment to soar.

Can happen any day, out of nowhere.

Per HL

Aberdeen-based firm noted a stronger second half of trading with "improving momentum" across its businesses.

Market cap around £1.67 bn
SALE EXPECTED to fetch £2bn +

Can pay down debt and pay dividends sooner .

Seems like a win win.

Any views on Countryside anyone?

https://www.youtube.com/watch?v=g77eCIdKlHY

Sinking but must be worth a nibble .

In the same boat but will reduce on next spike up to keep the average low for any retracement. Thinking 176p is a good top to aim for.

From sell to buy! Oops UBS - jokers.

At worst a hold, income income income. Cash cow and bid target.

There was a preclose update 7th January last year but none in 2020 or 2019 - just the results.

The next update seems to be 10th March (provisional).

Financial calendar
Upcoming events:

Event

Date
Preliminary announcement 2021 10/03/22*

Yes PFC will do well in increased orders and will rerate. WG. confirms this to be the case and as you may recall PFC had already told us this and new contracts continue.

2022 looking bullish towards £2 sometime and the next update should be eagerly anticipated.

Sometimes worth realising the family silverware when intrinsic and maybe at its peak.

The BoD are no Gordon Brown so perhaps maximising the potential or shareholders.

Will reduce with further rises and increase on falls. The business model is set for growth again.

DYOR

I assume a buying is lined up, hence the positive response

Wood Group to sell environment unit as core earnings fall
(Sharecast News) - Consulting and engineering company John Wood Group on Thursday reported a fall in core profit and said it was selling its built environment division after a review.
Adjusted core profits of around $550m - $560m, were down 9% on a like-for-like basis, with improved performance in consulting offset by lower profits in its projects and operations units.

The built environment operation, which helps companies assess environmental risk, could fetch £2bn pounds, according to media reports. Wood said a sale was "the best option to deliver value for our shareholders".

"It will also strengthen the group as we look to capitalise on the significant opportunities ahead of us, including in energy transition and industrial decarbonisation".

Revenue for the year to December 31 fell 9% to around $6.4bn, down 14% on a like-for-like basis, with growth in consulting and operations offset by a "significant decline in projects" as the company moved away from large-scale fixed price work.

Looking ahead, Wood said it expected activity levels to improve in 2022 across its business and had seen momentum in order in-take in the fourth quarter of 2021, including an improvement in projects.

"We expect our order book at 31 December 2021 to be significantly higher than 31 December 2020 with growth in all business units," it added.

I believe it is a bargain - but with covid delay impacting what should be an amazing story. Be patient.

Perhaps as I said allowing Lombard an out.

yes maybe but with an 11p average, I am rebuying my sales.

The lower the better, gap down, I top up.

Inflation will be passing, covid restrictions evaporating and debts reducing significantly.

Roll on 2023.

Yes I liked this too.

have trimmed from yesterday add on at close and hope this holds. Hedging bets, happy with results particularly outlook.

Projects expected decline as refoccussing to ST.

Overall good to go and will add again on any sub £2 pullback.

missed the sub 56p - well done

Smacks of letting Lombard escape.

That said I sold 80% at 64p+ and have just bought back a good tranche sub 57p.

GLA

Smith & Nephew SNATS – Consensus Indicates Potential 28.8% Upside
Broker Ratings

Charlotte Edwards
January 9, 2022
2:04 pm

Smith & Nephew SNATS found using ticker (SNN) now have 3 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 47 and 44 and has a mean target at 45.33. With the stocks previous close at 35.2 this would indicate that there is a potential upside of 28.8%. The 50 day MA is 34.2 and the 200 moving average now moves to 38.49. The company has a market cap of $15,688m. Company Website: https://www.smith-nephew.com

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.